| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
|
| ln Vitro |
In AML12 and LX2 cells, kahweol (20–40 μM; 24 hours) decreases TGF-β-induced CTGF protein production [1]. While Kahweol (20–40 μM; 1 hour) has no effect on expression in LX2 cells, it decreases TGF-β-induced phosphorylated Smad2/3 expression in AML12 cells [1]. In primary hepatocytes, kahweol (20–40 μM) only significantly lowers TGF-β-stimulated phospho-ERK and JNK expression [1]. In 3T3-L1 cells, kahweol (0-25 μg/ml; 6-24 hours) leads to a time-dependent increase in the phosphorylation of AMPK and its downstream target, acetyl-CoA carboxylase (ACC) [2]. Kahweol (0–25 μg/ml) regulates adipocyte development and lipid metabolism by substantially altering the protein expression of PPARγ, C/EBPα, FABP4, and FASN [2].
|
|---|---|
| Cell Assay |
Western Blot Analysis[2]
Cell Types: 3T3-L1 Cell Tested Concentrations: 0, 5, 10, 25 μg/ml Incubation Duration: Experimental Results: PPARγ, C/EBPα, FABP4 and FASN expression diminished in a dose-dependent manner. |
| References |
|
| Additional Infomation |
Kahweol is a diterpenoid with formula C20H26O3, isolated from the beans of Coffea arabica. It exhibits antioxidant, anti-inflammatory, anti-angiogenesis and anti-proliferative properties. It has a role as an angiogenesis inhibitor, an apoptosis inducer, an antioxidant, an anti-inflammatory agent, an antineoplastic agent and a plant metabolite. It is a diterpenoid, a member of furans, an organic heteropentacyclic compound, a tertiary alcohol and a primary alcohol.
Kahweol has been reported in Coffea congensis, Coffea sessiliflora, and other organisms with data available. |
| Molecular Formula |
C20H26O3
|
|---|---|
| Molecular Weight |
314.4186
|
| Exact Mass |
314.188
|
| CAS # |
6894-43-5
|
| Related CAS # |
6894-43-5;81760-47-6;
|
| PubChem CID |
114778
|
| Appearance |
Off-white to light yellow solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
476.6±45.0 °C at 760 mmHg
|
| Melting Point |
88-90 °C
|
| Flash Point |
242.0±28.7 °C
|
| Vapour Pressure |
0.0±1.3 mmHg at 25°C
|
| Index of Refraction |
1.623
|
| LogP |
3.38
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
23
|
| Complexity |
545
|
| Defined Atom Stereocenter Count |
6
|
| SMILES |
C[C@@]12C=CC3=C([C@H]1CC[C@]45[C@H]2CC[C@H](C4)[C@](C5)(CO)O)C=CO3
|
| InChi Key |
JEKMKNDURXDJAD-HWUKTEKMSA-N
|
| InChi Code |
InChI=1S/C20H26O3/c1-18-7-5-16-14(6-9-23-16)15(18)4-8-19-10-13(2-3-17(18)19)20(22,11-19)12-21/h5-7,9,13,15,17,21-22H,2-4,8,10-12H2,1H3/t13-,15-,17+,18-,19+,20+/m1/s1
|
| Chemical Name |
(1S,4S,12S,13R,16R,17R)-17-(hydroxymethyl)-12-methyl-8-oxapentacyclo[14.2.1.01,13.04,12.05,9]nonadeca-5(9),6,10-trien-17-ol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 33.33 mg/mL (~106.00 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.67 mg/mL (5.31 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 16.7 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1.67 mg/mL (5.31 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 16.7 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. View More
Solubility in Formulation 3: 1.67 mg/mL (5.31 mM) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1805 mL | 15.9023 mL | 31.8046 mL | |
| 5 mM | 0.6361 mL | 3.1805 mL | 6.3609 mL | |
| 10 mM | 0.3180 mL | 1.5902 mL | 3.1805 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
